Clinical Trial Update: Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sildenafil to increase exercise capacity in idiopathic pulmonary fibrosis with pulmonary hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Pulmonary Hypertension

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Pulmonary Fibrosis, Hypertension, Pulmonary | Phase 2 | Status: COMPLETED